quote:

Originally posted by Ngûnjiri®:
Jane,
iyo ni nduu?

onai didnt know,never heard bout it.its good now i've known.

Wa B,
I am just curious.Why should she ask him to use a CD if they are married?I was thinking that the pple who have different sex partners should use a CD and does it help prevent HPV?
[/QUOTE]

Jane,Sajini does not sound like the marrying type .You and I know that African men ,no offense are not all that when it comes to monogamy.Most of them believe that poligamy is IT.I do not blame them though.If their wives said no to being anyones second whatever,maybe things would be different.

If a man has more than one wife,the wives should insist on the husband using a CD cause they do not know who has been keeping the other wives satisfied while their husband was with one of them.After all, they say whats good for the goose is good for the gander too.

CDs are not 100% effective.They say that they protect at least 70 something percent so it is better than nothing.Its just like a vaccine.You take it for protection not cure.

By the way there is this new HPV vaccine.I will google it and paste it later.

Here it goes

The first vaccine that prevents some cervical cancer-causing forms of the human papilloma virus (HPV) in women, may also stop men from spreading the virus and contracting cancer.

Jennifer Mallory, a spokeswoman for Edelman, a New York City-based PR firm that represents Merck and Co., said the company is continuing to conduct clinical trials with the vaccine, called Gardasil, on males. It plans to seek Federal Drug Administration approval for use on boys and men once those trials are complete.

Mallory added that last month, Merck submitted a request to the FDA to update the labeling for Gardasil to include its effectiveness against another strain of HPV, one that is responsible for more than 10 percent of cervical cancers, as well as other types of gynecological cancers — vaginal and vulvar. Within 60 days, the FDA will determine whether it will accept the application for review.

According to a release about the update, more than 25,000 individuals have been studied over 10 years of clinical trials with the vaccine.

Currently, the vaccine is approved by the FDA for use in girls and women ages 9 to 26 for the prevention of HPV types 16 and 18, which have been linked to over 70 percent of cervical cancer cases; and HPV 6 and 11, which cause 90 percent of genital warts